Abstract 4004
Background
Upregulation of the receptor tyrosine kinase AXL has been linked with both minor treatment effect of PD-1 blockade and acquired resistance to BRAF inhibitors in melanoma. Bemcentinib is a first-in-class orally bioavailable selective inhibitor of AXL which is currently investigated in several phase II clinical trials. BGBIL006 (NCT02872259) is an open label phase Ib/II trial designed to explore whether combination with bemcentinib improves overall response rates to standard of care therapies in patients (pts) with metastatic melanoma (MM).
Methods
Dose escalation of bemcentinib in combination with 150mg twice daily/2mg daily dabrafenib/trametinib (D/T) in newly diagnosed, BRAF+, MM with high tumour load followed a 3 + 3 design (part 1). In part 2, pts were randomised 2:1 to receive D/T or pembro +/- bemcentinib at RP2D, respectively, based on mutation status and tumour load. Pts were allowed to switch D/T with pembrolizumab and vice versa upon progression (part 3). Tumour responses were assessed per investigator using RECIST v1.1. Plasma protein biomarker levels were measured using the DiscoveryMap v3.3 panel (Myriad RBM) in pts pre-dose and at C2D1.
Results
In part 1, 6 pts were enrolled first line (age 34-71, LDH > 1 x ULN 50%). There was 1 dose limiting toxicity (G3 rash) and an RP2D of bemcentinib in combination with D/T of 200mg daily bemcentinib with full dose D/T was confirmed. As of 2 May 18, a further 17 pts have been enrolled into part 2 of the study and four had progressed to part 3. Grade 3 treatment-related adverse events (AEs) were observed in 7 pts (30%). No G4 AEs or treatment related deaths occurred. Biomarkers candidates predicting treatment benefit were explored. Pre/post treatment changes of soluble proteins will be presented.
Conclusions
Bemcentinib RP2D (200 mg daily) is well tolerated in combination with both D/T and pembro without increased toxicity compared to either therapeutic approach alone. Further investigation of safety and efficacy as well as biomarker candidates is ongoing.
Clinical trial identification
NCT02872259.
Legal entity responsible for the study
Department for Oncology and Medical Physics, Haukeland University Hospital Bergen.
Funding
KLINBFORSK governmental funding.
Editorial Acknowledgement
Disclosure
G. Gausdal: Employee: BerGenBio. B.T. Gjertsen: Stock/ownership: Alden Cancer Therapy II, Kinn Therapeutics AS. J. Lorens: Ownership: BerGenBio ASA. All other authors have declared no conflicts of interest.
Resources from the same session
1978 - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.
Presenter: Kiyoshi Saeki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3682 - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)
Presenter: Annikka Weissferdt
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3319 - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma
Presenter: Min Hee Hong
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5130 - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma
Presenter: Myung-Won Lee
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4483 - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Presenter: Thomas Mrowiec
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1175 - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis.
Presenter: Naoko Sato
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1359 - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors
Presenter: Miriam López Gómez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2651 - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells
Presenter: Kohei Morita
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2233 - Somatic-stem transition of tumor cells is a key link in the metastasis
Presenter: Nicolai Litviakov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2601 - Profile of individuals who never undergo colorectal cancer screening
Presenter: Jérôme Viguier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract